Treating moderate to severe psoriasis - Best use of biologics

Research output: Contribution to journalArticlepeer-review


This review focuses on the efficacy, safety and best use of biologic agents in moderate-to-severe psoriasis. Recommendations from two recent guidelines are summarised. The NICE Guidelines 2012 provide recommendations on best practice for prescribing biologics. The German S3 Guidelines are based on a systematic review of published studies and report the efficacy of biologics and guidelines for treatment. Data on the safety of biologics are available for up to 5 years in psoriasis and are on the whole reassuring. Registry data is evolving and will provide data on safety to help inform long-term monitoring of patients with psoriasis on biologics agents. New anti-interleukin-17 (IL17) and anti-IL17RA biologics are in Phase 3 clinical trials and may prove to be more effective than existing biologics. © 2014 Informa UK Ltd.

Bibliographical metadata

Original languageEnglish
Pages (from-to)269-279
Number of pages10
JournalExpert review of clinical immunology
Issue number2
Publication statusPublished - Feb 2014